<DOC>
	<DOCNO>NCT02247349</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics , immunogenicity , antitumor activity pharmacodynamics BMS-986012 alone combination nivolumab patient relapsed/refractory SCLC .</brief_summary>
	<brief_title>BMS-986012 Relapsed/Refractory SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histological cytological confirm small cell lung cancer ( SCLC ) Performance Status 01 Adequate organ function Measurable disease Known suspect brain metastasis Small cell cancer lung origin Significant acute medical illness Uncontrolled significant cardiac disease Infection â‰¥ Grade 2 peripheral neuropathy Concomitant malignancy HIV related disease know suspected HIV+ Hepatitis B C infection ECG abnormality define protocol Allergies hypersensitivities monoclonal antibody , BMS986012 relate compound , include fucosylGM1 vaccine Nivolumab Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>